Yifan Pharmaceutical Co., Ltd. (SHE: 002019)
China
· Delayed Price · Currency is CNY 12.71
-0.22 (-1.70%)
Nov 13, 2024, 3:04 PM CST
Yifan Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 4,972 | 4,044 | 3,819 | 4,379 | 5,369 | 5,152 | Upgrade
|
| Other Revenue | 23.61 | 23.61 | 17.51 | 30.45 | 31.39 | 34.7 | Upgrade
|
| Revenue | 4,996 | 4,068 | 3,837 | 4,409 | 5,400 | 5,187 | Upgrade
|
| Revenue Growth (YoY) | 23.72% | 6.03% | -12.98% | -18.36% | 4.12% | 11.98% | Upgrade
|
| Cost of Revenue | 2,711 | 2,139 | 1,983 | 2,594 | 2,899 | 2,809 | Upgrade
|
| Gross Profit | 2,285 | 1,929 | 1,853 | 1,815 | 2,501 | 2,377 | Upgrade
|
| Selling, General & Admin | 1,686 | 1,503 | 1,435 | 1,297 | 1,111 | 1,059 | Upgrade
|
| Research & Development | 319.17 | 312.38 | 190.2 | 196.64 | 325.34 | 207.87 | Upgrade
|
| Other Operating Expenses | 60.28 | 32.37 | 27.05 | 37.24 | 42.11 | 32.95 | Upgrade
|
| Operating Expenses | 2,133 | 1,908 | 1,682 | 1,552 | 1,487 | 1,312 | Upgrade
|
| Operating Income | 151.32 | 20.93 | 171.35 | 262.68 | 1,014 | 1,065 | Upgrade
|
| Interest Expense | -18.16 | -75.55 | -85.85 | -74.59 | -71.07 | -70.42 | Upgrade
|
| Interest & Investment Income | 9.39 | 13.13 | 21.39 | 25.3 | 33.21 | 60.15 | Upgrade
|
| Currency Exchange Gain (Loss) | 14.5 | 14.5 | 50.19 | -17.77 | -18.06 | 3.9 | Upgrade
|
| Other Non Operating Income (Expenses) | -84.37 | -14.84 | -12.38 | -8.03 | -3.06 | -4.73 | Upgrade
|
| EBT Excluding Unusual Items | 72.68 | -41.83 | 144.69 | 187.59 | 954.93 | 1,054 | Upgrade
|
| Impairment of Goodwill | - | - | - | -11.9 | - | -46.03 | Upgrade
|
| Gain (Loss) on Sale of Investments | -9.57 | -15.06 | -17.63 | -4.49 | -0.01 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 34.38 | 2.57 | -0.56 | 14.83 | -0.04 | -0.85 | Upgrade
|
| Asset Writedown | -869.75 | -872.46 | -102.13 | -26.34 | -6.6 | -26.09 | Upgrade
|
| Other Unusual Items | 153.51 | 57.74 | 132.37 | 51.1 | 132.44 | 87.01 | Upgrade
|
| Pretax Income | -618.74 | -869.03 | 156.74 | 210.79 | 1,081 | 1,068 | Upgrade
|
| Income Tax Expense | 60.25 | 16.62 | 29.65 | -31.42 | 149.32 | 195.07 | Upgrade
|
| Earnings From Continuing Operations | -678.99 | -885.65 | 127.09 | 242.21 | 931.39 | 873.12 | Upgrade
|
| Minority Interest in Earnings | 347.46 | 334.58 | 64.13 | 36.18 | 37 | 30.35 | Upgrade
|
| Net Income | -331.54 | -551.07 | 191.22 | 278.4 | 968.39 | 903.47 | Upgrade
|
| Net Income to Common | -331.54 | -551.07 | 191.22 | 278.4 | 968.39 | 903.47 | Upgrade
|
| Net Income Growth | - | - | -31.32% | -71.25% | 7.19% | 22.51% | Upgrade
|
| Shares Outstanding (Basic) | 1,223 | 1,225 | 1,195 | 1,210 | 1,210 | 1,205 | Upgrade
|
| Shares Outstanding (Diluted) | 1,223 | 1,225 | 1,275 | 1,210 | 1,226 | 1,221 | Upgrade
|
| Shares Change (YoY) | -1.37% | -3.94% | 5.32% | -1.25% | 0.40% | 0.99% | Upgrade
|
| EPS (Basic) | -0.27 | -0.45 | 0.16 | 0.23 | 0.80 | 0.75 | Upgrade
|
| EPS (Diluted) | -0.27 | -0.45 | 0.15 | 0.23 | 0.79 | 0.74 | Upgrade
|
| EPS Growth | - | - | -34.78% | -70.89% | 6.76% | 21.31% | Upgrade
|
| Free Cash Flow | -74.41 | -155.5 | -70.21 | -270.51 | 392.8 | 71.17 | Upgrade
|
| Free Cash Flow Per Share | -0.06 | -0.13 | -0.06 | -0.22 | 0.32 | 0.06 | Upgrade
|
| Dividend Per Share | 0.100 | - | - | - | 0.050 | 0.100 | Upgrade
|
| Dividend Growth | - | - | - | - | -50.00% | -75.00% | Upgrade
|
| Gross Margin | 45.73% | 47.42% | 48.30% | 41.16% | 46.31% | 45.84% | Upgrade
|
| Operating Margin | 3.03% | 0.51% | 4.47% | 5.96% | 18.77% | 20.54% | Upgrade
|
| Profit Margin | -6.64% | -13.55% | 4.98% | 6.31% | 17.93% | 17.42% | Upgrade
|
| Free Cash Flow Margin | -1.49% | -3.82% | -1.83% | -6.14% | 7.27% | 1.37% | Upgrade
|
| EBITDA | 427.9 | 268.03 | 379.13 | 453.82 | 1,191 | 1,219 | Upgrade
|
| EBITDA Margin | 8.56% | 6.59% | 9.88% | 10.29% | 22.05% | 23.50% | Upgrade
|
| D&A For EBITDA | 276.58 | 247.09 | 207.78 | 191.14 | 177.01 | 153.69 | Upgrade
|
| EBIT | 151.32 | 20.93 | 171.35 | 262.68 | 1,014 | 1,065 | Upgrade
|
| EBIT Margin | 3.03% | 0.51% | 4.47% | 5.96% | 18.77% | 20.54% | Upgrade
|
| Effective Tax Rate | - | - | 18.92% | - | 13.82% | 18.26% | Upgrade
|
| Revenue as Reported | 4,996 | 4,068 | 3,837 | 4,409 | 5,400 | 5,187 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.